(S (PP (IN With) (NP (NP (DT the) (JJ fast) (NN development)) (PP (IN of) (NP (NNP COVID-19))) (PP (IN into) (NP (DT a) (JJ global) (NN pandemic))))) (, ,) (NP (NP (NNS scientists)) (PP (IN around) (NP (DT the) (NN globe)))) (VP (VBP are) (VP (ADVP (RB desperately)) (VBG searching) (PP (IN for) (NP (JJ effective) (JJ antiviral) (JJ therapeutic) (NNS agents))))) (. .))
(S (S (VP (VBG Bridging) (NP (NP (NNS systems) (NN biology)) (CC and) (NP (NN drug) (NN discovery))))) (, ,) (NP (PRP we)) (VP (VBP propose) (NP (NP (DT a) (JJ deep) (NN learning) (NN framework)) (PP (IN for) (NP (NP (JJ conditional) (FW de) (FW novo) (NN design)) (PP (IN of) (NP (NP (JJ antiviral) (NN candidate) (NNS drugs)) (VP (VBN tailored) (PP (IN against) (NP (VBN given) (JJ protein) (NNS targets)))))))))) (. .))
(S (ADVP (RB First)) (, ,) (NP (PRP we)) (VP (VP (VBP train) (NP (DT a) (JJ multimodal) (LST (NN ligand) (: â€”)) (NN protein) (VBG binding) (NN affinity) (NN model)) (PP (IN on) (S (VP (VBG predicting) (NP (NP (NNS affinities)) (PP (IN of) (NP (JJ antiviral) (NNS compounds))) (PP (TO to) (NP (VB target) (NNS proteins)))))))) (CC and) (VP (NN couple) (NP (DT this) (NN model)) (PP (IN with) (NP (JJ pharmacological) (NN toxicity) (NNS predictors))))) (. .))
(S (S (VP (VBG Exploiting) (NP (DT this) (JJ multi-objective)) (PP (IN as) (NP (NP (DT a) (NN reward) (NN function)) (PP (IN of) (NP (NP (DT a) (JJ conditional) (JJ molecular) (NN generator)) (PRN (-LRB- -LRB-) (VP (VBG consisting) (PP (IN of) (NP (CD two) (NNP VAEs)))) (-RRB- -RRB-)))))))) (, ,) (NP (PRP we)) (VP (VBP showcase) (NP (NP (DT a) (NN framework)) (SBAR (WHNP (WDT that)) (S (VP (VBZ navigates) (NP (DT the) (NN chemical) (NN space)) (PP (IN toward) (NP (NP (NNS regions)) (PP (IN with) (NP (RBR more) (JJ antiviral) (NNS molecules)))))))))) (. .))
(S (ADVP (RB Specifically)) (, ,) (NP (PRP we)) (VP (VBP explore) (NP (NP (DT a) (VBG challenging) (NN setting)) (PP (IN of) (S (VP (VBG generating) (NP (NNS ligands)) (PP (IN against) (NP (JJ unseen) (JJ protein) (NNS targets))))))) (PP (IN by) (S (VP (VBG performing) (NP (DT a) (NN leave-one-out-cross-validation)) (PP (IN on) (NP (CD 41) (JJ SARS-CoV-2-related) (NN target) (NNS proteins))))))) (. .))
(S (S (VP (VBG Using) (NP (JJ deep) (NNP RL)))) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN demonstrated) (SBAR (IN that) (S (PP (IN in) (NP (QP (CD 35) (IN out) (IN of) (CD 41)) (NNS cases))) (, ,) (NP (DT the) (NN generation)) (VP (VBZ is) (VP (VBN biased) (PP (NNS towards) (S (VP (VBG sampling) (NP (RBR more) (JJ binding) (NNS ligands))))) (, ,) (PP (IN with) (NP (NP (NP (DT an) (JJ average) (NN increase)) (PP (IN of) (NP (CD 83) (NN %)))) (VP (VBG comparing) (PP (TO to) (NP (DT an) (JJ unbiased) (NNP VAE)))))))))))) (. .))
(S (NP (PRP We)) (VP (VP (VBP present) (NP (NP (DT a) (NN case-study)) (PP (IN on) (NP (DT a) (JJ potential) (NNP Envelope-protein) (NN inhibitor))))) (CC and) (VP (VB perform) (SBAR (S (NP (NP (DT a) (JJ synthetic) (NN accessibility) (NN assessment)) (PP (IN of) (NP (DT the) (ADJP (JJS best) (JJ generated)) (NNS molecules)))) (VP (VBZ is) (VP (VBN performed) (SBAR (WHNP (IN that)) (S (VP (VBZ resembles) (NP (NP (DT a) (JJ viable) (NN roadmap)) (PP (IN towards) (NP (NP (DT a) (JJ rapid) (JJ in-vitro) (NN evaluation)) (PP (IN of) (NP (JJ potential) (JJ SARS-CoV-2) (NNS inhibitors))))))))))))))) (. .))
